JP2016513104A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513104A5 JP2016513104A5 JP2015557484A JP2015557484A JP2016513104A5 JP 2016513104 A5 JP2016513104 A5 JP 2016513104A5 JP 2015557484 A JP2015557484 A JP 2015557484A JP 2015557484 A JP2015557484 A JP 2015557484A JP 2016513104 A5 JP2016513104 A5 JP 2016513104A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- kir3dl2
- polypeptide
- ptcl
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 29
- 108090001123 antibodies Proteins 0.000 claims 29
- 102100012800 KIR3DL2 Human genes 0.000 claims 19
- 101710038955 KIR3DL2 Proteins 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 15
- 208000003002 Lymphoma, T-Cell, Peripheral Diseases 0.000 claims 10
- 201000007923 peripheral T-cell lymphoma Diseases 0.000 claims 10
- 210000004027 cells Anatomy 0.000 claims 9
- 230000003211 malignant Effects 0.000 claims 3
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 claims 2
- 102100012810 KIR3DL1 Human genes 0.000 claims 2
- 101710038974 KIR3DL1 Proteins 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 230000002500 effect on skin Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 1
- 201000009614 adult lymphoma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000006011 modification reaction Methods 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
- 210000004881 tumor cells Anatomy 0.000 claims 1
Claims (15)
- 個人における非皮膚末梢Ｔ細胞リンパ腫（ＰＴＣＬ）の処置または予防における使用のための、ＫＩＲ３ＤＬ２ポリペプチドに結合し、かつＫＩＲ３ＤＬ２発現腫瘍細胞を排除する抗体。
- 前記ＰＴＣＬが、腸症関連Ｔ細胞リンパ腫（ＥＡＴＬ）である、請求項１に記載の抗体。
- 前記ＰＴＣＬが、成人Ｔ細胞白血病またはリンパ腫（ＡＴＬ）である、請求項１に記載の抗体。
- 前記ＰＴＣＬが、ＨＴＬＶ＋ＡＴＬである、請求項３に記載の抗体。
- 請求項１〜４のいずれか一項に記載の抗体であって、個人におけるＰＴＣＬの処置または予防が、
ａ）ＰＴＣＬを有する前記個人内の悪性細胞のＫＩＲ３ＤＬ２ポリペプチドステータスを決定するステップおよび
ｂ）前記個人が、実質的な数の悪性細胞の表面上に発現されるＫＩＲ３ＤＬ２ポリペプチドを有するという決定に際して、ＫＩＲ３ＤＬ２ポリペプチドに結合する前記抗体を前記個人に投与するステップ
を含む、抗体。 - ＫＩＲ３ＤＬ２ポリペプチドが実質的な数の前記悪性細胞の表面上に発現されるかどうかを決定することが、末梢Ｔ細胞リンパ腫細胞を含む生物学的サンプルを前記個人から得、ＫＩＲ３ＤＬ２ポリペプチドに結合する抗体と前記細胞を接触させ、ＫＩＲ３ＤＬ２を発現する細胞を検出することを含む、請求項５に記載の抗体。
- 前記抗体が、ヒトＦｃγ受容体への結合を増強するアミノ酸修飾を含む、請求項１〜６のいずれか一項に記載の抗体。
- 前記抗体が、毒性の作用物質に連結される、請求項１〜７のいずれか一項に記載の抗体。
- 前記抗ＫＩＲ３ＤＬ２抗体が、ヒトＫＩＲ３ＤＬ２に結合するが、ヒトＫＩＲ３ＤＬ１に結合しない、請求項１〜８のいずれか一項に記載の抗体。
- 前記抗ＫＩＲ３ＤＬ２抗体は、配列番号１の野生型ＫＩＲ３ＤＬ２ポリペプチドと比較して、残基Ｐ１７９および／または残基Ｓ１８１に突然変異を有するＫＩＲ３ＤＬ２ポリペプチドへの結合が低下している、請求項１〜９のいずれか一項に記載の抗体。
- 前記抗ＫＩＲ３ＤＬ２抗体は、配列番号１の野生型ＫＩＲ３ＤＬ２ポリペプチドと比較して、残基Ｉ６０および／または残基Ｇ６２に突然変異を有するＫＩＲ３ＤＬ２ポリペプチドへの結合が低下している、請求項１〜１０のいずれか一項に記載の抗体。
- 前記抗ＫＩＲ３ＤＬ２抗体が、ＫＩＲ３ＤＬ２に、配列番号５および６の重鎖可変領域および軽鎖可変領域をそれぞれ有する抗体、配列番号３２および３３の重鎖可変領域および軽鎖可変領域をそれぞれ有する抗体、または配列番号１６および１７の重鎖可変領域および軽鎖可変領域をそれぞれ有する抗体と同じエピトープに結合する、請求項１〜１１のいずれか一項に記載の抗体。
- 非皮膚ＰＴＣＬを診断するまたはモニターするためのインビトロでの方法であって、ＰＴＣＬ細胞を含む生物学的サンプルを提供するステップ、ヒトＫＩＲ３ＤＬ２ポリペプチドに結合する抗体と前記細胞を接触させるステップ、およびＫＩＲ３ＤＬ２を発現する細胞を検出するステップを含む方法。
- ＫＩＲ３ＤＬ２ポリペプチドに結合する前記抗体が、ヒトＫＩＲ３ＤＬ２ポリペプチドに結合するが、ヒトＫＩＲ３ＤＬ１ポリペプチドに結合しない抗体である、請求項１３に記載の方法。
- ＫＩＲ３ＤＬ２ポリペプチドに結合する前記抗体が、配列番号１６および１７の重鎖可変領域および軽鎖可変領域をそれぞれ有する抗体と競合する、請求項１３または１４に記載の方法。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361766798P | 2013-02-20 | 2013-02-20 | |
| US61/766,798 | 2013-02-20 | ||
| US201361831809P | 2013-06-06 | 2013-06-06 | |
| US61/831,809 | 2013-06-06 | ||
| PCT/EP2014/053340 WO2014128221A1 (en) | 2013-02-20 | 2014-02-20 | A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513104A JP2016513104A (ja) | 2016-05-12 |
| JP2016513104A5 true JP2016513104A5 (ja) | 2017-02-02 |
| JP6360077B2 JP6360077B2 (ja) | 2018-07-18 |
Family
ID=50156759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015557484A Active JP6360077B2 (ja) | 2013-02-20 | 2014-02-20 | 末梢ｔ細胞リンパ腫の処置における使用のためのｋｉｒ３ｄｌ２に特異的に結合する化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20160002345A1 (ja) |
| EP (3) | EP3521312B1 (ja) |
| JP (1) | JP6360077B2 (ja) |
| CN (1) | CN105026427B (ja) |
| AU (1) | AU2014220668B2 (ja) |
| CA (1) | CA2899241C (ja) |
| DK (2) | DK3521312T3 (ja) |
| ES (2) | ES2730011T3 (ja) |
| WO (1) | WO2014128221A1 (ja) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2859017B1 (en) | 2012-06-08 | 2019-02-20 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| EP2897980B1 (en) | 2012-09-19 | 2019-11-06 | Innate Pharma | Kir3dl2 binding agents |
| CN105026427B (zh) | 2013-02-20 | 2019-12-24 | 依奈特制药公司 | 特异性结合至kir3dl2的化合物用于治疗外周t细胞淋巴瘤 |
| JP6865582B2 (ja) * | 2013-05-29 | 2021-04-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｋｉｒ３ｄｌ２は皮膚及び非皮膚末梢ｔ細胞リンパ腫のサブセットをそれぞれ予防及び治療するために有用なバイオマーカー及び治療標的である |
| US9764039B2 (en) | 2013-07-10 | 2017-09-19 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| BR112016021066B1 (pt) * | 2014-03-14 | 2024-01-02 | Innate Pharma | Anticorpo ou fragmento de anticorpo que se liga a um polipeptídeo kir3dl2, composição farmaceutica e uso de um anticorpo ou composição farmacêutica |
| WO2016030488A1 (en) * | 2014-08-27 | 2016-03-03 | Innate Pharma | Treatment of celiac disease |
| US10487153B2 (en) | 2015-06-10 | 2019-11-26 | National Research Council Of Canada | Carbonic anhydrase IX-specific antibodies and uses thereof |
| EP3325967B1 (en) | 2015-07-24 | 2019-12-04 | Innate Pharma | Methods for detecting tissue infiltrating nk cells |
| RU2018130757A (ru) | 2016-01-27 | 2020-02-27 | Сутро Биофарма, Инк. | Конъюгаты антитела к cd74, композиции, содержащие конъюгаты антитела к cd74, и способы использования конъюгатов антитела к cd74 |
| FI3464368T3 (fi) * | 2016-06-02 | 2023-09-12 | Bristol Myers Squibb Co | Anti-pd-1-vasta-aineen käyttö yhdistelmänä anti-cd30-vasta-aineen kanssa lymfooman hoitamisessa |
| AU2017345203A1 (en) | 2016-10-21 | 2019-05-02 | Innate Pharma | Treatment with anti-KIR3DL2 agents |
| WO2019023316A1 (en) * | 2017-07-26 | 2019-01-31 | Sutro Biopharma, Inc. | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA |
| CN108319816B (zh) * | 2018-02-27 | 2021-04-23 | 广州大学 | 一种基于基因通路识别小分子核糖核酸的方法 |
| EP3914620A1 (en) | 2019-01-22 | 2021-12-01 | Innate Pharma | Treatment of t cell lymphoma |
| US20240117042A1 (en) * | 2021-04-05 | 2024-04-11 | Innate Pharma | Immunohistochemistry methods and kir3dl2-specific reagents |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US5599790A (en) * | 1992-06-11 | 1997-02-04 | The Scripps Research Institute | Fibrinogen γ chain polypeptide and compositions thereof |
| WO1997041898A1 (en) | 1996-05-03 | 1997-11-13 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| MXPA02003108A (es) | 1999-09-25 | 2003-10-14 | Univ Iowa Res Found | Acidos nucleicos inmunoestimuladores. |
| AU1922902A (en) | 2000-12-18 | 2002-07-01 | Inst Nat Sante Rech Med | Novel means for the diagnosis and therapy of CTCL |
| SI1425389T1 (sl) * | 2001-08-23 | 2012-02-29 | Genmab As | Humana protitelesa, specifična za interlevkin 15 (IL-15) |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| ATE536188T1 (de) | 2002-08-14 | 2011-12-15 | Macrogenics Inc | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| JP2004126818A (ja) | 2002-09-30 | 2004-04-22 | Toshiba Corp | 電子機器システム、電池ユニットおよび電池ユニットの動作制御方法 |
| US7411045B2 (en) * | 2002-11-19 | 2008-08-12 | A&G Pharmaceutical, Inc. | Autocrine growth factor receptor antibodies and methods |
| WO2004063351A2 (en) | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| KR20060038461A (ko) * | 2003-07-24 | 2006-05-03 | 이나뜨 파르마 | Ｎｋ 세포 강화 화합물을 사용하여 치료용 항체의 효율을높이는 방법 및 조성물 |
| EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| JP5367982B2 (ja) | 2004-04-16 | 2013-12-11 | マクロジェニクス，インコーポレーテッド | ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| WO2005110474A2 (en) | 2004-05-10 | 2005-11-24 | Macrogenics, Inc. | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| EP2287195B1 (en) * | 2004-07-01 | 2019-05-15 | Novo Nordisk A/S | Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| PT1836225E (pt) * | 2005-01-06 | 2012-01-10 | Novo Nordisk As | Agentes de ligação a kir e métodos de utilização dos mesmos |
| JP2008541770A (ja) | 2005-06-03 | 2008-11-27 | ジェネンテック・インコーポレーテッド | 改変したフコシル化レベルを有する抗体の産生方法 |
| ES2526811T3 (es) | 2005-08-10 | 2015-01-15 | Macrogenics, Inc. | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos |
| FR2894982A1 (fr) | 2005-12-16 | 2007-06-22 | Lab Francais Du Fractionnement | Procede de preparation d'anticorps selectifs des recepteurs fc activateurs |
| EP1977003A4 (en) | 2005-12-22 | 2009-11-11 | Dermagene Oy | DISEASE-RELATED METHODS AND MEDIUM |
| MX2008009220A (es) | 2006-01-17 | 2008-10-10 | Biolex Therapeutics Inc | Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas. |
| EP1999470A4 (en) | 2006-03-10 | 2009-08-19 | Macrogenics Inc | IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF |
| US7786270B2 (en) | 2006-05-26 | 2010-08-31 | Macrogenics, Inc. | Humanized FcγRIIB-specific antibodies and methods of use thereof |
| CA2656224C (en) | 2006-06-26 | 2018-01-09 | Macrogenics, Inc. | Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof |
| EP1878747A1 (en) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
| BRPI0719953B8 (pt) * | 2006-10-02 | 2021-05-25 | Regeneron Pharma | anticorpos humanos de alta afinidade para receptor de il-4 humano |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| DK2379598T3 (en) * | 2009-01-19 | 2015-06-15 | Innate Pharma | Anti-kir3d antibodies |
| KR102184713B1 (ko) * | 2009-07-17 | 2020-12-01 | 오메로스 코포레이션 | 보체 활성화의 억제제로서의 masp 이소형 |
| NZ701539A (en) | 2010-03-04 | 2015-04-24 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2012006341A2 (en) * | 2010-07-06 | 2012-01-12 | Aveo Pharmaceuticals, Inc. | Anti-ron antibodies |
| EP2897980B1 (en) * | 2012-09-19 | 2019-11-06 | Innate Pharma | Kir3dl2 binding agents |
| WO2014044681A1 (en) * | 2012-09-19 | 2014-03-27 | Innate Pharma | Kir3dl2 binding agents |
| CN105026427B (zh) | 2013-02-20 | 2019-12-24 | 依奈特制药公司 | 特异性结合至kir3dl2的化合物用于治疗外周t细胞淋巴瘤 |
| JP6865582B2 (ja) | 2013-05-29 | 2021-04-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｋｉｒ３ｄｌ２は皮膚及び非皮膚末梢ｔ細胞リンパ腫のサブセットをそれぞれ予防及び治療するために有用なバイオマーカー及び治療標的である |
| BR112016021066B1 (pt) | 2014-03-14 | 2024-01-02 | Innate Pharma | Anticorpo ou fragmento de anticorpo que se liga a um polipeptídeo kir3dl2, composição farmaceutica e uso de um anticorpo ou composição farmacêutica |
| AU2017345203A1 (en) | 2016-10-21 | 2019-05-02 | Innate Pharma | Treatment with anti-KIR3DL2 agents |
-
2014
- 2014-02-20 CN CN201480009772.XA patent/CN105026427B/zh active Active
- 2014-02-20 AU AU2014220668A patent/AU2014220668B2/en active Active
- 2014-02-20 WO PCT/EP2014/053340 patent/WO2014128221A1/en active Application Filing
- 2014-02-20 JP JP2015557484A patent/JP6360077B2/ja active Active
- 2014-02-20 EP EP19163475.7A patent/EP3521312B1/en active Active
- 2014-02-20 EP EP14706017.2A patent/EP2958941B1/en active Active
- 2014-02-20 DK DK19163475.7T patent/DK3521312T3/da active
- 2014-02-20 EP EP21166926.2A patent/EP3896088A1/en active Pending
- 2014-02-20 ES ES14706017T patent/ES2730011T3/es active Active
- 2014-02-20 US US14/769,158 patent/US20160002345A1/en not_active Abandoned
- 2014-02-20 CA CA2899241A patent/CA2899241C/en active Active
- 2014-02-20 ES ES19163475T patent/ES2878749T3/es active Active
- 2014-02-20 DK DK14706017.2T patent/DK2958941T3/da active
-
2017
- 2017-06-15 US US15/623,572 patent/US10174112B2/en active Active
-
2019
- 2019-01-07 US US16/240,906 patent/US11078275B2/en active Active
-
2021
- 2021-07-29 US US17/388,052 patent/US20210363248A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513104A5 (ja) | ||
| Szurek et al. | Differences in expression level of helios and neuropilin-1 do not distinguish thymus-derived from extrathymically-induced CD4+ Foxp3+ regulatory T cells | |
| Hong et al. | Re-evaluation of PD-1 expression by T cells as a marker for immune exhaustion during SIV infection | |
| Miller et al. | Tumor-infiltrating Merkel cell polyomavirus-specific T cells are diverse and associated with improved patient survival | |
| Lundholm et al. | Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion | |
| Logozzi et al. | High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients | |
| Chou et al. | Accelerated aging in HIV/AIDS: novel biomarkers of senescent human CD8+ T cells | |
| JP2018083821A5 (ja) | ||
| Song et al. | HIV protective KIR3DL1/S1-HLA-B genotypes influence NK cell-mediated inhibition of HIV replication in autologous CD4 targets | |
| MD3652215T2 (ro) | Moleculă polipeptidică îmbunătăţită cu specificitate duală | |
| Van Teijlingen et al. | Sequence variations in HIV-1 p24 Gag-derived epitopes can alter binding of KIR2DL2 to HLA-C* 03: 04 and modulate primary natural killer cell function | |
| JP2012143232A5 (ja) | ||
| WO2018023100A3 (en) | Anti-idiotypic antibodies against anti-cd19 antibodies | |
| NZ619883A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
| EP2534257A4 (en) | METHOD OF IDENTIFYING AND ISOLATING CELLS FOR THE EXPRESSION OF POLYPEPTIDES | |
| Christophersen et al. | Healthy HLA-DQ2. 5+ subjects lack regulatory and memory T cells specific for immunodominant gluten epitopes of celiac disease | |
| Yang et al. | Involvement of CD244 in regulating CD4+ T cell immunity in patients with active tuberculosis | |
| Xiao et al. | Metabolism-dependent ferroptosis promotes mitochondrial dysfunction and inflammation in CD4+ T lymphocytes in HIV-infected immune non-responders | |
| CL2012001980A1 (es) | Uso de un anticuerpo monoclonal anti-cd44 o fragmento de unión del mismo, en el tratamiento del carcinoma escamocelular de cabeza y cuello (hnscc) en un mamífero, donde el hnscc se distingue según la expresión de cd44. | |
| Anderson et al. | Epigenetic modification of the FoxP3 TSDR in HAM/TSP decreases the functional suppression of Tregs | |
| MX353464B (es) | Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles. | |
| Wauquier et al. | HLA-C-restricted viral epitopes are associated with an escape mechanism from KIR2DL2+ NK cells in Lassa virus infection | |
| Ayo et al. | Killer cell immunoglobulin-like receptors and their HLA ligands are related with the immunopathology of Chagas disease | |
| WO2012017082A3 (de) | Anti-la antikörper und ihre anwendung zum immunotargeting |